Ipamorelin: Growth Hormone Secretagogue Mechanism and Research Overview
An independent science-journalism review of ipamorelin research — how this selective GH secretagogue works, what the preclinical and limited clinical literature shows, and its current regulatory standing.
Ipamorelin is one of the better-characterised growth hormone secretagogues on paper. The catch: almost all of that characterisation is in rats, and the one human safety study from the early 2000s was never published. So the cleanest part of its story is the part nobody can read. Let’s start there.
What ipamorelin is
Ipamorelin (structure: Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic five-amino-acid peptide. It switches on the growth hormone secretagogue receptor (GHSR-1a) in the pituitary, the same receptor ghrelin uses, and that tells somatotroph cells to release growth hormone.
It came out of a programme trying to fix a problem with the earlier growth hormone-releasing peptides, GHRP-6 and GHRP-2. Those raised cortisol and prolactin alongside GH. Ipamorelin’s selling point was selectivity: it pushed GH without dragging the stress hormones up with it. That was the headline finding in its early pharmacology.
The rat data, and the human gap
The foundational work is a 1998 paper in the European Journal of Endocrinology by Raun and colleagues. In rat pituitary cell cultures and live rodents, ipamorelin produced strong, dose-dependent GH release at a potency on par with GHRP-6, while raising cortisol, prolactin, and ACTH far less. The selectivity seemed to come from how ipamorelin hits GHSR-1a differing from ghrelin’s broader neuroendocrine reach. In rats.
A 2000 follow-up in the Journal of Endocrinology by Svensson and colleagues looked at bone in adult female rats. Twelve weeks of ipamorelin raised bone mineral content and density at the lumbar vertebrae and femur versus controls, with no measured change in uterus or adrenal weight. The authors read that as favourable tissue selectivity. Still rats. Still preclinical.
Human data is the weak point. A small Phase I study in the early 2000s looked at safety and GH pharmacokinetics in healthy adults. It was never published in peer-reviewed form, which means you can’t actually check it. No large clinical trial has shown efficacy in people for any indication.
Where regulators landed — and when
Ipamorelin isn’t on the PCAC July 23–24, 2026 docket — but the reason isn’t that nobody looked. PCAC reviewed ipamorelin acetate at its October 29, 2024 meeting and voted against inclusion on the 503A bulk drug substances list. The FDA’s standard reasoning pattern applied: insufficient human safety data, mechanistic concerns about unintended endocrine effects, and lack of reproducible efficacy data outside small or open-label trials. Treating this as not-on-the-docket misses the part that matters — the docketed review already happened, and the vote came out against.
WADA’s 2026 Prohibited List S2 category — Growth Hormone Releasing Factors and their analogs — covers ipamorelin whether the exact name is spelled out or not. If you compete, treat it as prohibited, in and out of competition.
The unanswered questions
This is the honest part, so read it twice.
The human pharmacokinetics aren’t characterised in the published literature. How ipamorelin is absorbed after a subcutaneous injection, its half-life in people, its human dose-response: none of that is in peer-reviewed studies.
Long-term effects on GH-axis regulation in humans aren’t established. Whether chronic use blunts the natural GH-IGF-1 axis through feedback inhibition, receptor desensitisation, or some other adaptation is unknown clinically.
The animal-to-human jump is a real problem here, as with every secretagogue. Rat pituitary GH dynamics aren’t human GH pulse physiology, and the difference changes how much of the preclinical efficacy you can extrapolate.
And safety outside healthy young adults is uncharted. Older adults, people with metabolic conditions, anyone with a prior endocrine diagnosis: not characterised.
Where ipamorelin lands
Ipamorelin’s preclinical profile is genuinely interesting. Selective GH release with cortisol and prolactin mostly spared is a meaningful pharmacological trait, if it holds in people. That if is doing all the work.
The honest framing, if you’re tracking this: the rat data is clean and consistent, the human efficacy column is thin, the one human safety study is unpublished, and the compounding rules are in flux. The foundation is worth watching. The clinical picture is still mostly empty.
Join the waitlist
No spam — we email when something changes, and not otherwise.
You're on the list. Check your inbox for the first briefing.
Sources
- Ipamorelin, the first selective growth hormone secretagogue — Raun et al., Eur J Endocrinol (1998)
Raun et al. (1998, Eur J Endocrinol) reported ipamorelin as the first selective GH secretagogue. In rat pituitary cell cultures and live rodents, ipamorelin produced strong dose-dependent GH release at potency comparable to GHRP-6, while raising cortisol, prolactin, and ACTH far less.
- The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats — Svensson et al., J Endocrinol (2000)
Svensson et al. (2000, J Endocrinol) reported that ipamorelin and GH-releasing peptide-6 increased bone mineral content in adult female rats. Twelve weeks of ipamorelin raised bone mineral content and density at the lumbar vertebrae and femur, with no measured change in uterus or adrenal weight.
- FDA Federal Register: Pharmacy Compounding Advisory Committee — Notice of Meeting (July 23–24, 2026)
A 2026 Federal Register notice announces the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026 to evaluate bulk drug substances nominated for the Section 503A list, including BPC-157, and establishes a public docket for comment.